Surrogate End Points in Pulmonary Arterial Hypertension: Assessing the Response to Therapy
作者： Jennifer L. Snow , Steven M. Kawut
DOI: 10.1016/J.CCM.2006.11.005
关键词:
摘要: Recent discoveries in the disease pathophysiology of pulmonary arterial hypertension have been translated into effective therapies tested clinical trials. The studies focused on surrogate and intermediate end points, thought to reflect quantity quality life, respectively. authors present necessary requirements for establishing reliability validity such points before they may be used dependably. also review available data, strengths, weaknesses potential hypertension.
elsevier.com
sci-hub.se 参考文章(114)
Victor G De Gruttola, Pamela Clax, David L DeMets, Gregory J Downing, Susan S Ellenberg, Lawrence Friedman, Mitchell H Gail, Ross Prentice, Janet Wittes, Scott L Zeger, Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials Controlled Clinical Trials. ,vol. 22, pp. 485- 502 ,(2001) , 10.1016/S0197-2456(01)00153-2
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework* Clinical Pharmacology & Therapeutics. ,vol. 69, pp. 89- 95 ,(2001) , 10.1067/MCP.2001.113989
Marius M Hoeper, Ronald J Oudiz, Andrew Peacock, Victor F Tapson, Sheila G Haworth, Adaani E Frost, Adam Torbicki, End Points and Clinical Trial Designs in Pulmonary Arterial Hypertension Clinical and Regulatory Perspectives Journal of the American College of Cardiology. ,vol. 43, pp. 179- 201 ,(2004) , 10.1016/J.JACC.2004.02.010
GERALD SIMONNEAU, ROBYN J. BARST, NAZZARENO GALIE, ROBERT NAEIJE, STUART RICH, ROBERT C. BOURGE, ANNE KEOGH, RONALD OUDIZ, ADAANI FROST, SHELMER D. BLACKBURN, JAMES W. CROW, LEWIS J. RUBIN, Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine. ,vol. 165, pp. 800- 804 ,(2002) , 10.1164/AJRCCM.165.6.2106079
Richard N Channick, Gérald Simonneau, Olivier Sitbon, Ivan M Robbins, Adaani Frost, Victor F Tapson, David B Badesch, Sébastien Roux, Maurizio Rainisio, Frédéric Bodin, Lewis J Rubin, Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. The Lancet. ,vol. 358, pp. 1119- 1123 ,(2001) , 10.1016/S0140-6736(01)06250-X
Lewis J. Rubin, Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol) Annals of Internal Medicine. ,vol. 112, pp. 485- 491 ,(1990) , 10.7326/0003-4819-112-7-485
John G. Lainchbury, Richard W. Troughton, Christopher M. Frampton, Timothy G. Yandle, Amjad Hamid, M. Gary Nicholls, A. Mark Richards, NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial. European Journal of Heart Failure. ,vol. 8, pp. 532- 538 ,(2006) , 10.1016/J.EJHEART.2006.04.004
Srijoy Mahapatra, Rick A. Nishimura, Paul Sorajja, Stephen Cha, Michael D. McGoon, Relationship of Pulmonary Arterial Capacitance and Mortality in Idiopathic Pulmonary Arterial Hypertension Journal of the American College of Cardiology. ,vol. 47, pp. 799- 803 ,(2006) , 10.1016/J.JACC.2005.09.054
Lawrence M. Boxt, Jose Katz, Thomas Kolb, Ferenc P. Czegledy, Robyn J. Barst, Direct quantitation of right and left ventricular volumes with nuclear magnetic resonance imaging in patients with primary pulmonary hypertension Journal of the American College of Cardiology. ,vol. 19, pp. 1508- 1515 ,(1992) , 10.1016/0735-1097(92)90611-P
Tim Higenbottam, Frank Wells, Derek Wheeldon, John Wallwork, LONG-TERM TREATMENT OF PRIMARY PULMONARY HYPERTENSION WITH CONTINUOUS INTRAVENOUS EPOPROSTENOL (PROSTACYCLIN) The Lancet. ,vol. 323, pp. 1046- 1047 ,(1984) , 10.1016/S0140-6736(84)91452-1